Sympathomimetics for acute severe asthma: should only beta 2-selective agonists be used?

Area of Science:

• Pharmacology and Therapeutics
• Respiratory Medicine

Background:

• Sympathomimetics are essential for acute asthma management.
• Aerosolized administration offers bronchodilation with fewer systemic effects than parenteral routes.
• Cardiostimulation is a dose-limiting adverse effect of sympathomimetics in high-dose therapy.

Purpose of the Study:

• To review the pharmacology, adverse effects, and toxicities of selected beta agonists.
• To evaluate clinical studies on the use of beta agonists in acute, severe asthma.
• To determine the preferential use of selective beta 2 agonists in specific asthma populations.

Main Methods:

• Review of pharmacological data for beta agonists.
• Analysis of adverse effects and toxicities.
• Evaluation of relevant clinical studies.

Main Results:

• Aerosolized sympathomimetics provide significant bronchodilation in acute severe asthma.
• Cardiostimulation is a major dose-limiting factor, despite broncho-selectivity.
• Available evidence suggests preferential use of selective beta 2 agonists.

Conclusions:

• Selective beta 2 agonists are recommended for acute, severe asthma requiring high-dose beta agonists.
• While ideal studies are lacking, current evidence supports this preferential use.
• Careful consideration of cardiostimulation risks is necessary in high-dose therapy.